ResultsIQ

ResultsIQ › Latest results › Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited Q4 FY26 results deck summary

NSE: ONESOURCE · BSE: 544292

Results deck of 13 May 2026, summarised by AI from the filing.

Reaffirms FY28 outlook of $400 million organic revenue and ~40% EBITDA margin.

Key takeaways

  1. FY28 guidance Reaffirms FY28 outlook of $400 million organic revenue and ~40% EBITDA margin.
  2. Semaglutide India semaglutide launches and Canada approvals support continued momentum into FY27.

Original filing on BSE

Onesource Specialty Pharma Limited Q1 FY27 results

As filed: Revenue ₹449 cr (+37% year on year), EBITDA ₹123 cr (+39% year on year), PAT ₹25.0 cr, EBITDA margin 27.5% (+25 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹428 cr (+1% year on year), EBITDA ₹91.9 cr (−49% year on year), PAT ₹4.6 cr (−100% year on year), EBITDA margin 21.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −9.9% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹290 cr (−26% year on year), EBITDA ₹17.3 cr (−88% year on year), PAT −₹88.7 cr, EBITDA margin 6.0% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 23% from last quarter. Share price after the results: −25.0% in 30 days (Nifty 500: +0.7%).
  • Q2 FY26: Revenue ₹376 cr (+300% year on year), EBITDA ₹107 cr, PAT ₹10.0 cr, EBITDA margin 28.5% (+1,000 bps). Score 88 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 50% of PBT. Tax rate -83%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.6% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹321 cr, EBITDA ₹80.0 cr, PAT ₹25.0 cr, EBITDA margin 24.9%. Not scored. No result for the same quarter last year. Share price after the results: −4.1% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹477 cr, EBITDA ₹237 cr, PAT ₹174 cr, EBITDA margin 49.7%. Not scored. No result for the same quarter last year. Share price after the results: +17.5% in 30 days (Nifty 500: +2.8%).
  • Q3 FY25: Revenue ₹337 cr, EBITDA ₹101 cr, PAT −₹73.0 cr, EBITDA margin 30.0%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹68.0 cr, EBITDA ₹0.0 cr, PAT −₹40.0 cr, EBITDA margin 0.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Onesource Specialty Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.